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Abstract
Aims/hypothesis—Physical activity improves oxidative capacity and exerts therapeutic 
beneficial effects, particularly in the context of metabolic diseases. The peroxisome proliferator-
activated receptor γ (PPARγ) coactivator-1α (PGC-1α) and the nuclear receptor PPARβ/δ have 
both been independently discovered to play a pivotal role in the regulation of oxidative 
metabolism in skeletal muscle, though their interdependence remain unclear. Hence, our aim was 
to determine the functional interaction between these two factors in mouse skeletal muscle in vivo.
Methods—Adult male control mice, PGC-1α muscle-specific transgenic (mTg) mice, PPARβ/δ 
muscle-specific knockout (mKO) mice and the combination PPARβ/δ mKO + PGC-1α mTg were 
studied under basal conditions and following PPARβ/δ agonist administration and acute exercise. 
Whole body metabolism was assessed by indirect calorimetry and blood analysis, while magnetic 
resonance was used to measure body composition. Quantitative PCR and western blot were used 
to determine gene expression and intracellular signaling. Proportion of oxidative muscle fiber was 
determined by NADH staining.
Results—Agonist-induced PPARβ/δ activation was only disrupted by PPARβ/δ knockout. We 
also found that the disruption of the PGC-1α-PPARβ/δ axis does not affect whole body 
metabolism under basal conditions. As expected, PGC-1α mTg mice exhibited higher exercise 
performance, peak oxygen consumption and lower blood lactate levels following exercise, though 
PPARβ/δ mKO+PGC-1α mTg mice showed a similar phenotype. Similarly, we found that 
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PPARβ/δ was dispensable for PGC-1α-mediated enhancement of an oxidative phenotype in 
skeletal muscle.
Conclusions/interpretation—Collectively, these results indicate that PPARβ/δ is not an 
essential partner of PGC-1α in the control of skeletal muscle energy metabolism.
Keywords
skeletal muscle metabolism; nuclear receptors; coregulators; exercise
Introduction
The regulation of energy metabolism in skeletal muscle is highly controlled by the 
peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) [1]. 
PGC-1α drives the expression of genes involved in catabolic processes leading to aerobic 
ATP synthesis [1], while concomitantly promoting anabolic processes, including de novo 
lipogenesis [2]. Once activated, PGC-1α boosts the activity of different transcription factors 
to control gene programs resembling an endurance-trained phenotype in skeletal muscle [1, 
3]. These adaptations are associated with an enhanced oxidative capacity, which contributes 
to an increased skeletal muscle fatigue resistance ex vivo and exercise performance in vivo 
[4-6]. Importantly, exercise is in fact one of the most efficient stimuli to induce PGC-1α in 
skeletal muscle [3].
Among the transcription factors regulated by PGC-1α, the nuclear receptor PPARβ/δ has 
been proposed to be a key partner of PGC-1α in the regulation of skeletal muscle 
metabolism and function, though mainly based on cell culture and pharmacological studies 
[7]. PGC-1α acts as a coactivator of PPARβ/δ [8-10], while PPARβ/δ can directly regulate 
PGC-1α expression [11, 12], indicating that this nuclear receptor acts both upstream as well 
as downstream of PGC-1α. Furthermore, transgenic mouse models for PPARβ/δ exhibit a 
similar phenotype compared to their counterparts for PGC-1α [4, 5, 13, 14]. Nevertheless, 
although the PGC-1α-PPARβ/δ axis appears to play a key role in the regulation of energy 
metabolism, the epistatic interaction between these proteins is currently unclear. We 
therefore aimed at directly assessing the functional interplay between PGC-1α and PPARβ/δ 
in the regulation of skeletal muscle oxidative metabolism in vivo.
Methods
Animals
Mice were housed in a conventional facility with a 12 h night/day cycle, with free access to 
food/water. Experiments were performed on adult male mice with approval of the Swiss 
authorities. PGC-1α muscle-specific transgenic (mTg) mice have been described previously 
[5]. PPARβ/δ muscle-specific knockout (mKO) mice were generated by crossing PPARβ/
δloxP/loxP mice with HSA-Cre transgenic mice [11]. Finally, PGC-1α mTg and HSA-Cre 
positive PPARβ/δloxP/loxP mKO mice were crossed to generate PPARβ/δ mKO+PGC-1α 
mTg mice. PPARβ/δloxP/loxP animals without Cre and PGC-1α transgene expression were 
used as control (CON) mice. All mice had mixed sv129 and C57BL/6 background. 
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Genotypes were confirmed through PCR procedures (data not shown) and qPCR analysis in 
kidney and skeletal muscle (Fig. 1a, b).
PPARβ/δ agonist
CON mice were subjected to an intra-peritoneal injection of either 0.9% NaCl (control) or 1 
mg/kg of body weight of the PPARβ/δ agonist GW0742 (Tocris #2229, Bristol, UK), as 
previously described [15]. Muscles were collected 8 h following drug administration.
Body composition analysis
Lean and fat mass were measured via magnetic resonance (EchoMRI™, Houston, TX, 
USA).
Blood and plasma analysis
Blood samples were collected under basal conditions or immediately after maximal exercise 
from fed and/or overnight fasted mice, as previously described [9].
Glucose and insulin tolerance test
Intra-peritoneal glucose tolerance tests (GTT) were carried out by injecting 2 g/kg of body 
weight of glucose after 16 h of fasting. Insulin tolerance tests (ITT) were performed by 
injecting 0.8 U/kg of body weight of insulin (Novo Nordisk, Bagsvaerd, Denmark) after 6 h 
of fasting.
Indirect calorimetry
Animals were individually housed in a Comprehensive Lab Animal Monitoring System 
(Columbus Instruments, Columbus, OH, USA) during an acclimatization period of 48 h with 
free access to food and water. Subsequently, indirect calorimetry was performed during 48 h 
and data analyzed with the Oxymax software (Columbus Instruments).
Maximal exercise test
Exercise tests were performed as previously described [9]. Briefly, two days after 
acclimatization animals performed a maximal exercise test in a closed treadmill (Columbus 
Instruments), allowing the measurement of peak oxygen consumption (VO2peak) and 
respiratory exchange ratio (RER).
Histology
NADH staining was performed on 10 μm cross sections from tibialis anterior by exposing 
them to 1 mg/ml NADH (Sigma, St. Louis, MO, USA) in the presence of 1 mg/ml nitro blue 
tetrazolium (Sigma).
Non-esterified fatty acids (NEFA) measurement
Plasma NEFA were measured using a commercial kit (HR Series NEFA-HR(2), Wako 
Diagnostics, Richmond, VA, USA), according to manufacturer’s instructions. Blood 
samples were collected under basal conditions and following 1 h of treadmill running at 13 
m min-1 with 5° slope.
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Intramyocellular triacylglycerol (IMTG) extraction
Quadriceps IMTG were extracted by standard procedures using a solid-phase extraction 
column (UPTI-CLEAN NH2-S 100mg/1mL SPE Columns, Interchim, Montluçon, France) 
and quantified with a commercial kit (Triglyceride enzymatique PAP 150, Biomerieux, 
Marcy-l’Etoile, France), according to manufacturer’s instructions.
RNA isolation and quantitative PCR (qPCR)
Total RNA isolation from fed (ad libitum) animals and qPCR analysis was performed by 
standard procedures [9]. Sequences of qPCR primers are depicted in Table S1. Analysis was 
performed by the ΔΔCT method using TATA binding protein (TBP) as endogenous control. 
TBP transcript levels were not different between genotypes or experimental conditions.
Protein isolation and western blot
Protein isolation and western blot was conducted as previously described [9]. Proteins were 
detected with primary antibodies to Akt (Cell Signaling, Danvers, MA, USA; #9272), p-
AktT308 (Cell Signaling #4056), AMPKα (Cell Signaling #2603), p-AMPKαT172 (Cell 
Signaling #2535, USA), total OXPHOS (Abcam #ab110413, USA) and eEF2 (Cell 
Signaling: #2332).
Statistical analysis
Values are expressed as mean ± standard error of the mean (SEM). Statistical significance 
was determined with unpaired two-tailed t-tests or one-way ANOVA with Tukey’s post-hoc 
test. Significance was considered with a p < 0.05.
Results
PGC-1α overexpression and PPARβ/δ deletion in mouse skeletal muscle
To elucidate the functional requirement for PPARβ/δ in the metabolic adaptations induced 
by PGC-1α, we crossed PPARβ/δ muscle-specific knockout (mKO) mice with PGC-1α 
muscle-specific transgenic (mTg) mice, referred as PPARβ/δ mKO+PGC-1α mTg animals. 
As expected, both PPARβ/δ mKO and PPARβ/δ mKO+PGC-1α mTg mice showed a 
reduction of Pparβ/δ mRNA specifically in skeletal muscle, while Pgc-1α mRNA was up-
regulated by ~12 fold in skeletal muscle of PGC-1α mTg and PPARβ/δ mKO+PGC-1α mTg 
mice compared to control (CON) animals (Fig. 1a, b). To validate the functional 
consequence of PPARβ/δ deletion in skeletal muscle, we assessed the effects of the 
PPARβ/δ agonist GW0742 on the expression levels of PPARβ/δ target genes [7, 16]. Acute 
treatment with GW0742 did not affect Pparβ/δ mRNA in gastrocnemius and plantaris 
muscles whereas uncoupling protein 3 (Ucp3) mRNA levels were induced in CON, but not 
in PPARβ/δ mKO mice (Fig. 1c, d). Moreover, as previously reported [16], angiopoietin-like 
4 (Angptl4) was up-regulated by GW0742 in a way that was partially dependent on PPARβ/δ 
(Fig. 1c, d). Importantly, PPARβ/δ deletion did not affect the transcript levels of Pparα and 
Pparγ (Fig. 1e). We subsequently measured the expression levels of other transcription 
factors and coactivators regulating metabolism, including the estrogen related receptors 
(Err), mitochondrial transcription factor A (Tfam), Pgc-1β and PGC-1-related coactivator 
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(Prc). The expression of these genes was altered in skeletal muscle of PGC-1α mTg and 
PPARβ/δ mKO+PGC-1α mTg mice, thus independent of PPARβ/δ ablation (Fig. 1e).
Effects of skeletal muscle disruption of the PGC-1α-PPARβ/δ axis on whole body 
metabolism
Body composition assessment revealed equal body weight, fat mass and lean mass in 
PPARβ/δ mKO, PGC-1α mTg, PPARβ/δ mKO+PGC-1α mTg and CON mice (Fig. 2a). 
Analysis of plasma triacylglycerol (TG), cholesterol (CHOL), low-density lipoproteins 
(LDL) and high-density lipoproteins (HDL) during fed and fasted state exhibited no 
differences except for a significant decrease in fed CHOL in the PPARβ/δ mKO+PGC-1α 
mTg mice (Fig. 2b, c). Moreover, indirect calorimetry during 48 h revealed no differences in 
VO2 or RER between any of the genotypes (Fig. 2d, e, electronic supplementary material 
(ESM) Fig. 1a, b).
Pharmacological activation of PPARβ/δ attenuates the detrimental effects of obesity and 
type 2 diabetes on systemic glucose homeostasis [13, 17, 18]. Compared to CON mice, 
neither glucose nor insulin tolerance tests were affected by PGC-1α overexpression and/or 
PPARβ/δ deletion in skeletal muscle in mice fed a regular chow diet (Fig. 2f, g, ESM Fig. 
1c, d). Moreover, we did not find any differences in blood glucose levels in fed mice of the 
four different genotypes (Fig. 2h). These findings were corroborated by unchanged 
expression of genes involved in glucose transport and catabolism such as the glucose 
transporter 4 (Glut4), TBC1 domain family member 1 (Tbc1d1), phosphofructokinase (Pfk) 
and hexokinase 2 (Hk2) in skeletal muscle of PPARβ/δ mKO, PGC-1α mTg and PPARβ/δ 
mKO+PGC-1α mTg mice (Fig. 2i). In contrast, Tbc1d4 (also known as Akt substrate of 160 
kDa, As160) was significantly up-regulated in PGC-1α mTg animals (Fig. 2i). Finally, we 
observed an increase in total Akt protein levels following PGC-1α overexpression, with no 
substantial effect of PPARβ/δ deletion (Fig. 2j, ESM Fig. 1e). Consistently, PGC-1α 
overexpression slightly decreased relative AktT308 phosphorylation levels, though this effect 
was not statistically significant (ESM Fig. 1f). These data hence suggest that the PGC-1α-
PPARβ/δ axis is not essential for the modulation of whole body metabolism and glucose 
homeostasis under basal conditions in chow fed animals.
Modulation of skeletal muscle metabolism by the PGC-1α-PPARβ/δ axis
skeletal muscle PGC-1α and PPARβ/δ have been proposed to be key regulators of exercise 
performance and lactate metabolism [19, 20]. Consequently, we next assessed exercise 
performance in treadmill-based tests, which revealed a higher exercise performance in 
PGC-1α mTg mice as expected (Fig. 3a, b, c). Interestingly, PPARβ/δ muscle knockout did 
not reduce this difference when PPARβ/δ mKO+PGC-1α mTg mice were compared to CON 
animals (Fig. 3a, b, c). Moreover, VO2 was significantly enhanced in PGC-1α mTg and 
PPARβ/δ mKO+PGC-1α mTg mice during maximal exercise (Fig. 3d), thus altered by 
PGC-1α independent of PPARβ/δ. In contrast, the decrease in the RER in PGC-1α mTg 
animals was attenuated by concomitant PPARβ/δ deletion (Fig. 3e). Blood lactate 
concentration increased following maximal exercise in CON animals (Fig. 3f). This effect 
was attenuated in PPARβ/δ mKO mice and virtually abolished in both PGC-1α mTg and 
PPARβ/δ mKO+PGC-1α mTg mice (Fig. 3f). Similarly, pre-exercise blood lactate levels 
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were reduced only in the mouse models with elevated skeletal muscle PGC-1α (Fig. 3f). 
Consistently, lactate dehydrogenase A (Ldha) and monocarboxylic acid transporters 4 
(Mct4) mRNA levels were reduced only by PGC-1α overexpression in skeletal muscle, 
while in the same mice, Ldhb and Mct1 were up-regulated (Fig. 3g) reflecting an attenuated 
lactate production as well as higher catabolism. In order to assess substrate availability, we 
measured IMTG content and consistent with the function of PGC-1α in de novo lipogenesis 
[2] both PGC-1α mTg and PPARβ/δ mKO+PGC-1α mTg mice showed elevated IMTG 
levels, though PPARβ/δ knockout had no effect (Fig. 3h). Finally, we measured plasma 
levels of NEFA pre- and post-exercise. Exercise significantly increased plasma NEFA levels 
in PPARβ/δ mKO mice, while CON and PPARβ/δ mKO+PGC-1α mTg mice showed a trend 
toward an increase (Fig. 3i). These data show that, in response to maximal exercise, skeletal 
muscle PGC-1α is a pivotal regulator of whole body metabolism, mainly in a PPARβ/δ 
independent manner.
Next, we determined the relevance of PGC-1α and PPARβ/δ interaction in the regulation of 
skeletal muscle metabolism. We therefore determined the mRNA levels of genes regulating 
skeletal muscle oxidative metabolism, several of which have been suggested to be both 
PGC-1α and PPARβ/δ targets. Interestingly, we observed that PPARβ/δ deletion in skeletal 
muscle did not change the transcript abundance of genes involved in the TCA cycle, β-
oxidation and electron transport chain (ETC) (Fig. 4a, b). In contrast, most of these genes 
were strongly up-regulated by PGC-1α overexpression in a PPARβ/δ independent manner 
(Fig. 4a, b). The assessment of protein content of different components of mitochondrial 
complexes supports mRNA data, though the overall effects were milder (Fig. 4c, ESM Fig. 
2a). We then assessed the metabolic muscle phenotype by determining the proportion of 
oxidative fiber using NADH staining, which revealed a higher oxidative activity and 
proportion of oxidative fibers in PGC-1α mTg and PPARβ/δ mKO+PGC-1α mTg mice 
independent of a functional PPARβ/δ gene (Fig. 4d). Total protein content and 
phosphorylation levels of the key metabolic regulator AMP-activated protein kinase 
(AMPK) were not different in PPARβ/δ mKO, PGC-1α mTg or PPARβ/δ mKO+PGC-1α 
mTg mice, suggesting no altered energy status in any of these models (Fig. 4e, ESM Fig. 2b, 
c). We finally explored the relevance of the PGC-1α-PPARβ/δ axis in the context of the 
PPARβ/δ agonist GW0742-induced gene expression. As shown in the ESM Fig. 2d, 
GW0742 enhanced the expression of the PPARβ/δ targets Angptl4 and Ucp3, whereas it did 
not affect the mRNA levels of the key regulators of oxidative metabolism. Moreover, the 
effects of PGC-1α overexpression on gene expression were not affected by GW0742 (ESM 
Fig. 2d). Finally, as expected, PPARβ/δ gene ablation likewise abrogated any effect of the 
synthetic ligand (ESM Fig. 2d, Fig. 1c and 1d).
Discussion
The oxidative phenotype of skeletal muscle is strongly linked to physical activity levels and 
it has been associated with health beneficial effects in metabolic diseases and other 
pathologies. Even though the molecular mechanisms controlling exercise-induced adaptation 
in skeletal muscle have not been fully elucidated, PGC-1α is thought to promote 
mitochondrial function, myofibrillar gene expression, vascularization and other gene 
programs that are characteristic of oxidative muscle fibers [1]. Interestingly, PPARβ/δ is 
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able to recapitulate several of these effects [7], though the functional interaction between 
PGC-1α and PPARβ/δ has not been elucidated in this tissue so far. We now provide strong 
evidence indicating almost complete PPARβ/δ independence of PGC-1α overexpression on 
the metabolic phenotype of skeletal muscle.
Importantly, supporting our hypothesis, contrary to the effects observed in PGC-1α muscle-
specific transgenic mice, the enhancement of skeletal muscle oxidative metabolism is 
weaker in a bona fide muscle-specific PPARβ/δ gain-of-function mouse model [14]. 
Moreover, ligand-based activation of PPARβ/δ only increases exercise performance in 
trained mice, but not in sedentary animals [10]. Interestingly, oxidative metabolism and 
exercise performance can be boosted by fusing the PPARβ/δ protein to the heterologous 
VP16 activation domain that strongly increases its transcriptional activity in the absence of 
ligand or coactivator recruitment [13]. These data demonstrate that the reported functions of 
PPARβ/δ upstream and downstream of PGC-1α thereby are dispensable for PGC-1α 
function in an overexpression context. These observations are consistent with cell culture-
based experiments showing that PGC-1α strongly increased oxidative metabolism in the 
absence of PPARβ/δ in skeletal muscle cells [21]. It appears hence that PGC-1α regulates 
skeletal muscle oxidative metabolism by increasing the transcriptional activity of alternative 
transcription factors, some of which might even compensate for the loss of PPARβ/δ. In fact, 
Pparα, Errα and Errγ were significantly up-regulated in both PGC-1α mTg and PPARβ/δ 
mKO+ PGC-1α mTg skeletal muscle, suggesting that these transcription factors might play 
a more relevant function in this context. Importantly, our results indicate that PPARβ/δ 
deletion by itself does not result in a compensatory activation of such related transcription 
factors. In fact, PPARβ/δ mKO animals do not exhibit an up-regulation of PPARs, ERRs 
and TFAM in skeletal muscle. In addition, several target genes of these transcription factors 
were unaltered in PPARβ/δ mKO mice.
The contribution of PPARβ/δ to the regulation of skeletal muscle metabolism seems to be 
more relevant in the context of ligand-induced activation. Accordingly, PPARβ/δ activation 
with synthetic ligands is an efficient treatment for metabolic disorders [13, 17, 18, 22], 
though it remains unclear whether this effect is mediated by skeletal muscle PPARβ/δ. 
Conversely, overexpression of PGC-1α in skeletal muscle is insufficient to evoke similar 
therapeutic benefits in young mice and even accelerates the development of insulin 
resistance when such animals are fed a high-fat diet [23], unless the mice are concomitantly 
exercised [24]. In old animals however, overexpression of PGC-1α in muscle prevents age-
induced insulin resistance [25]. These findings indicate that in some pathological settings, 
PPARβ/δ activation might be more relevant than PGC-1α, in particular in the absence of 
physical activity.
Surprisingly, in our study, PPARβ/δ mKO animals had a similar phenotype compared to 
CON mice, with minimal or no changes in body composition, blood parameters and gene 
expression. In contrast, Shuler et al. have reported higher body weight and fat, in addition to 
increased serum levels of glucose, insulin and TG in the same mouse model [11]. 
Intriguingly, similar discrepancies have been reported in global PPARβ/δ KO mouse models 
in regard to whole body metabolism assessed under basal conditions [18, 26-29]. These 
differences in the phenotype of PPARβ/δ KO mouse models in chow fed sedentary condition 
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might stem from different environmental factors (e.g. diet and temperature) that could lead 
to a partial PPARβ/δ activation in CON animals and thus lead to more pronounced 
phenotypic differences in metabolic parameters when compared to KO mice. Importantly, 
most of the effects of skeletal muscle PPARβ/δ deletion reported by Schuler et al. on energy 
metabolism are observed following high-fat diet feeding and/or in old mice [11]. Moreover, 
in the same study, the phenotype of adult PPARβ/δ mKO mice fed chow diet is rather mild 
and not substantially different to our results, which is reflected by the magnitude and 
variability of the data [11].
During exercise, skeletal muscle exerts a bigger impact on whole body metabolism. 
Accordingly, PGC-1α mTg mice exhibit a higher VO2 and lower RER during treadmill 
running, reflecting an enhanced oxidative capacity and increased fatty acid oxidation [4]. 
Interestingly, while the PGC-1α-mediated improvement in VO2 during exercise is 
maintained in the absence of a functional PPARβ/δ gene, knockout of PPARβ/δ attenuated 
the decrease in the RER in PPARβ/δ mKO+ PGC-1α mTg mice. In line with our 
observations, it has been shown that PPARβ/δ overexpression in skeletal muscle does not 
affect VO2 and RER during treadmill running [20]. Moreover, PPARβ/δ has been proposed 
to specifically regulate fatty acid metabolism and only to a smaller extent other oxidative 
metabolic genes in cultured muscle cells [21]. Surprisingly, the effect of PPARβ/δ knockout 
on RER during maximal exercise appears to be unrelated to mRNA level of genes 
controlling fatty acid transport and oxidation. Interestingly, PPARβ/δ deletion attenuated the 
up-regulation of Pdk4 induced by PGC-1α overexpression. Importantly, skeletal muscle 
PDK4 has been extensively shown to be a key regulator of fatty acid oxidation during 
exercise [30], suggesting a possible mechanism by which PPARβ/δ modulates RER and thus 
energy substrate utilization during maximal exercise. It should be noted that PPARβ/δ 
knockout induced the up-regulation of Pdk4, an effect that supports the idea that this nuclear 
receptor can actively repress target genes in the absence of ligand [16, 31]. Together, these 
data suggest that the effects of skeletal muscle PGC-1α on VO2 are not dependent of 
PPARβ/δ, even though this nuclear receptor appears to be partially involved in the PGC-1α-
mediated increase in β-oxidation during exercise. In addition, our findings support previous 
data suggesting that PGC-1α-controlled lactate metabolism is predominantly regulated by 
ERRα and not PPARβ/δ [19].
In summary, our results reveal important insights into the regulatory networks that control 
skeletal muscle plasticity. Here, we show that in normal/physiological conditions, PPARβ/δ 
is dispensable for the effect of PGC-1α on skeletal muscle remodeling. Importantly, the 
different therapeutic effects of PPARβ/δ and PGC-1α in the context of metabolic diseases 
during sedentary vs. exercise/aging state, strongly suggest that the relative importance of 
these molecules in controlling the metabolic phenotype of skeletal muscle varies 
significantly depending of the physiological and pathological context. Therefore, we hope 
that these findings will allow a more targeted dissection and modulation of skeletal muscle 
plasticity in health and disease in the future.
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Abbreviations
AMPK AMP-activated protein kinase
ANGPTL4 angiopoietin-like 4
CHOL Cholesterol
CON control mice
ERR estrogen related receptors
ETC electron transport chain
GLUT4 glucose transporter 4
GTT glucose tolerance tests
HK2 hexokinase 2
ITT Insulin tolerance tests
LDHA lactate dehydrogenase A
LDHB lactate dehydrogenase B
MCT1 monocarboxylic acid transporters 1
MCT4 monocarboxylic acid transporters 4
mKO PPARβ/δ muscle-specific knockout
mTg PGC-1α muscle-specific transgenic
PFK phosphofructokinase
PGC-1α PPARγ coactivator-1α
PGC-1β PPARγ coactivator-1β
PPARα peroxisome proliferator-activated receptor α
PPARβ/δ peroxisome proliferator-activated receptor β/δ
PPARγ peroxisome proliferator-activated receptor γ
PRC PGC-1-related coactivator
RER respiratory exchange ratio
TBC1D1 TBC1 domain family member 1
TBC1D4 TBC1 domain family member 4
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TBP TATA binding protein
TFAM mitochondrial transcription factor A
TG triglycerides
UCP3 uncoupling protein 3
VO2peak peak oxygen consumption
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Fig. 1. 
PGC-1α and PPARβ/δ mouse models. (a and b) Pgc-1α and Pparβ/δ mRNA levels in 
kidney, gastrocnemius (GAS) and tibialis anterior (TA) (n = 6 per group). (c and d) Pparβ/δ, 
Ucp3 and Angptl4 mRNA levels in GAS and plantaris (PL) 8 h after the injection of 0.9% 
NaCl (as control) or 1 mg/kg of body weight of the PPARβ/δ agonist GW0742 (n = 6 per 
group). (e) mRNA level of different transcriptional regulators in GAS (n = 6 per group). In 
a, b and e CON: white, PPARβ/δ mKO: white with stripes, PGC-1α mTg: grey, PPARβ/δ 
mKO+ PGC-1α mTg: black. In c and d CON+NaCl: white, PPARβ/δ mKO+NaCl: black, 
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CON+ GW0742: grey, PPARβ/δ mKO+ GW0742: black with white stripes. Values are 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. In a, c and d ***p<0.001 vs. CON 
and/or PGC-1α mTg for same tissue/treatment.
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Fig. 2. 
Body composition, systemic parameters and glucose handling. (a) Assessment of body 
composition (n = 10-12 per group). (b and c) Plasma concentration of TAG, CHOL, LDL 
and HDL under fed and fasted conditions (n = 10-12 per group). (d and e) Measurement of 
VO2 (d) and RER (e) over a period of 48 h (n = 10-14 per group). (f-h) Blood glucose levels 
during glucose (f) and insulin tolerance tests (g). (h) Blood glucose levels in fed animals (n 
= 10-12 per group). (i) Gastrocnemius mRNA levels of genes involved in glucose 
metabolism (n = 6 per group). (j) Western blot assessment of Akt phosphorylation status in 
gastrocnemius (n = 6 per group). In a, b, c, h and I CON: white, PPARβ/δ mKO: white with 
stripes, PGC-1α mTg: grey, PPARβ/δ mKO + PGC-1α mTg: black. In d – g CON: black 
continuous line, PPARβ/δ mKO: black discontinuous line, PGC-1α mTg: grey continuous 
line, PPARβ/δ mKO + PGC-1α mTg: grey discontinuous line. Values are mean ± SEM. *p 
< 0.05, **p < 0.01. In f §p < 0.05 PPARβ/δ mKO vs. PGC-1α mTg; ‡‡‡p < 0.001 PPARβ/δ 
mKO vs. PPARβ/δ mKO + PGC-1α mTg.
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Fig. 3. 
Skeletal muscle PGC-1α modulates whole body metabolism during maximal exercise. (a, b, 
c) Maximal speed, time and work achieved during exercise tests to exhaustion (n = 10-12 
per group). (d and e) Measurement of VO2 and RER during the maximal exercise test (n = 
10-12 per group). (f) Blood lactate levels before (PRE) and after (POST) maximal exercise 
(n = 10-12 per group). (g) mRNA levels of key genes of lactate metabolism in 
gastrocnemius (n = 6 per group). (h) Quadriceps IMTG content (n = 5 per group). (i) Plasma 
levels of NEFA before (PRE) and after (POST) exercise (n = 4-6 per group). In a, b, c, f, g, 
h and I CON: white, PPARβ/δ mKO: white with stripes, PGC-1α mTg: grey, PPARβ/δ 
mKO + PGC-1α mTg: black. In d and e CON: black continuous line, PPARβ/δ mKO: black 
discontinuous line, PGC-1α mTg: grey continuous line, PPARβ/δ mKO + PGC-1α mTg: 
grey discontinuous line. Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. In d 
and e *p < 0.05, **p < 0.01, ***p < 0.001 CON vs. PGC-1α mTg; ¶p < 0.05, ¶¶p < 0.01 
CON vs. PPARβ/δ mKO+ PGC-1α mTg; §p < 0.05, §§§p < 0.001 PPARβ/δ mKO vs. 
PGC-1α mTg; ‡‡p < 0.01 PPARβ/δ mKO vs. PPARβ/δ mKO+ PGC-1α mTg.
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Fig. 4. 
Oxidative metabolism of gastrocnemius is enhanced by PGC-1α even in the absence of 
PPARβ/δ. (a and b) mRNA levels of genes regulating oxidative and fatty acid metabolism (n 
= 6 per group). (c) Western blot analysis of key proteins regulating the ETC (n = 6 per 
group). (d) Assessment of oxidative muscle fibers (dark blue) via NADH staining (n = 3 per 
group). (e) Western blot analysis of AMPK phosphorylation status (n = 6 per group). In a 
and b CON: white, PPARβ/δ mKO: white with stripes, PGC-1α mTg: grey, PPARβ/δ mKO 
+ PGC-1α mTg: black. Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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